GSC
KERX

Ground Swell Capital’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Ground Swell Capital’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-200
Closed -$3K – 2988
2014
Q2 		$3K Buy
+200
New +$2.83K 0.01% 1383

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Ground Swell Capital's KERX Position: Q3 2014 in Review

Ground Swell Capital sold out of Keryx Biopharmaceuticals Inc (KERX) in Q3 2014, closing a stake of 200 shares — an estimated $3K sold.

Ground Swell Capital first reported a position in KERX in Q2 2014 and held it in 1 quarter. The position peaked at $3K in Q2 2014. 140 funds tracked by Wall St. Rank hold KERX as of Q3 2014.

  • Ground Swell Capital reported no remaining Keryx Biopharmaceuticals Inc position as of Q3 2014 after selling out during the quarter.
  • Ground Swell Capital sold 200 Keryx Biopharmaceuticals Inc shares in Q3 2014, an estimated $3K.
  • Ground Swell Capital first reported a position in Keryx Biopharmaceuticals Inc in Q2 2014 and held it in 1 quarter.
  • Ground Swell Capital's Keryx Biopharmaceuticals Inc position peaked at $3K in Q2 2014.
  • 140 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q3 2014.

Based on Ground Swell Capital's 13F filing for Q3 2014, filed 6 Nov 2014.